
https://www.science.org/content/blog-post/only-connect
# Only Connect
25 Nov 2019

## 1. SUMMARY
This commentary discusses the persistent challenges in structure-based drug design, particularly the difficulty of accurately predicting small-molecule binding affinities from X-ray crystal structures alone, despite massive commercial incentives to solve this problem. The author highlights how traditional structural analysis struggles with ambiguous hydrophobic contacts, solvation effects, conformational changes, and entropy-enthalpy trade-offs.

The article focuses on a 2019 Roche/Cambridge Crystallographic Data Center study analyzing the Protein Data Bank (PDB) to systematically identify "nonclassical" intermolecular interactions. Using improved statistical approaches accounting for directionality and occurrence frequency, the researchers found evidence for previously underappreciated interactions: sigma-hole halogen-carbonyl interactions, aryl fluorine contacts with arginine and carbonyl groups, nitrile-arginine/indole interactions, and sulfonyl oxygen-amide backbone contacts. Importantly, the study also identified interactions that occur at rates *worse* than chance—providing guidance on what to avoid in ligand design.

## 2. HISTORY
Subsequent to this 2019 commentary, the understanding and use of nonclassical interactions in drug design has continued to advance, though specific FDA-approved drugs based predominantly on these particular interactions are not readily documented in broad literature. Fragment-based drug discovery (FBDD) has maintained steady progress as an established platform in biopharmaceutical research, with companies continuing to use structural data and PDB mining to guide design pipelines.

The systematic curation of the PDB and critical assessment of protein-ligand structures has remained an active area, with ongoing efforts to improve data quality and develop better statistical frameworks for identifying meaningful interactions from structural noise. Computational approaches for virtual screening have increasingly incorporated diverse interaction types beyond classic hydrogen bonding and hydrophobic contacts.

However, the fundamental challenge highlighted in the article—accurately predicting binding affinities from static structures—remains largely unsolved, with structure-based design continuing to be an iterative, empirical process. No revolutionary breakthrough has fundamentally changed this paradigm, though incremental improvements in computational methods and structural databases have been made. The focus on "unfavorable" interactions has gained wider appreciation in drug design workflows.

## 3. PREDICTIONS
The article contained several implicit and explicit predictions:

• **Prediction**: That systematic mining of structural databases would continue revealing new interaction types and refining computational drug design approaches.  
**Outcome**: Database mining and statistical analysis of structural data has continued, with improved computational tools and larger datasets. However, no paradigm-shifting discoveries in fundamentally new interaction types have emerged that dramatically changed drug discovery success rates.

• **Prediction**: That attention to "unfavorable" interactions (those occurring worse than chance) would prove valuable for avoiding design pitfalls.  
**Outcome**: This perspective has been increasingly adopted in drug design workflows, with computational tools incorporating repulsive or disfavored interaction terms.

• **Prediction**: That identifying preferred geometries for nonclassical interactions would help refine virtual screening and structure-based design.  
**Outcome**: Virtual screening methodologies have evolved to include more diverse interaction types, though the core challenge of binding affinity prediction accuracy persists.

• **Prediction**: That the underlying difficulty in predicting binding constants from crystal structures would remain challenging despite billion-dollar incentives.  
**Outcome**: This has proven accurate. Structure-based drug design remains valuable but still requires empirical validation, and binding affinity prediction from static structures continues to be an active research challenge.

## 4. INTEREST
Rating: **6/10**
The article provides useful technical insight for specialists in structural biology and computational chemistry, highlighting genuine challenges in drug design and discussing relevant molecular interactions. However, it ranks in the middle deciles because it focuses on methodology refinement rather than breakthrough discoveries, and the described insights have had moderate rather than transformative impact on drug discovery outcomes.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20191125-only-connect.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_